JP2012529298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529298A5 JP2012529298A5 JP2012515109A JP2012515109A JP2012529298A5 JP 2012529298 A5 JP2012529298 A5 JP 2012529298A5 JP 2012515109 A JP2012515109 A JP 2012515109A JP 2012515109 A JP2012515109 A JP 2012515109A JP 2012529298 A5 JP2012529298 A5 JP 2012529298A5
- Authority
- JP
- Japan
- Prior art keywords
- loop
- antigen
- domain
- recombinant
- domain monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 20
- 102000038129 antigens Human genes 0.000 claims 20
- 108091007172 antigens Proteins 0.000 claims 20
- 239000000178 monomer Substances 0.000 claims 16
- 241001263478 Norovirus Species 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 241000702670 Rotavirus Species 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (17)
- 挿入された外来タンパク質またはポリペプチド抗原を含む少なくとも１個の表面ループを有するノロウイルス（ＮＯＲ）Ｐドメインモノマーを含む、組換え抗原−Ｐドメインモノマー。
- ＮＯＲ Ｐドメインモノマーが第一のループ、第二のループおよび第三のループを含み、かつ、該少なくとも１個の表面ループが該第一のループ、該第二のループおよび該第三のループからなる群より選択される、請求項１の組換え抗原−Ｐドメインモノマー。
- ＮＯＲ ＰドメインモノマーがＮＯＲ株ＶＡ３８７のＰドメインであり、該第一のループがループ１（Ｉ２９３−Ｈ２９７）であり、該第二のループがループ２（Ｔ３７１−Ｄ３７４）であり、該第三のループがループ３（Ｄ３９１−Ｎ３９４）である、請求項２の組換え抗原−Ｐドメインモノマー。
- 挿入された外来タンパク質またはポリペプチド抗原がロタウイルス（ＲＶ）ＶＰ８抗原である、請求項１の組換え抗原−Ｐドメインモノマー。
- 挿入された外来タンパク質またはポリペプチド抗原が少なくとも２個の類似のまたは異なる抗原を含む、請求項１の組換え抗原−Ｐドメインモノマー。
- 該少なくとも２個の抗原が異なるものである、請求項５の組換え抗原−Ｐドメインモノマー。
- ２４個のＰドメインモノマーからなる抗原−Ｐ粒子であって、該２４個のＰドメインモノマーが、挿入された外来タンパク質またはポリペプチド抗原を含む少なくとも１個の表面ループを有するノロウイルス（ＮＯＲ）Ｐドメインモノマーである少なくとも１個の組換え抗原−Ｐドメインモノマーを含み、且つ所望により１個以上の野生型ＮＯＲ Ｐドメインモノマーを含んでもよく、ここで、該抗原−Ｐ粒子は抗原単独の免疫原性と比較して抗原の免疫原性を向上させうるものである、抗原−Ｐ粒子。
- 異なる修飾をされた２個以上の組換え抗原−Ｐドメインモノマーを含む、請求項７の抗原−Ｐ粒子。
- 少なくとも１個の表面ループが３個のループであり、該３個のループの各々が、挿入された複数の異なる外来抗原を含む、請求項１の組換え抗原−Ｐドメインモノマー。
- 少なくとも１個の表面ループ中に、挿入された外来リガンドまたはシグナルペプチドをさらに含む、請求項１の組換え抗原−Ｐドメインモノマー。
- 挿入された外来リガンドまたはシグナルペプチドが、特定の臓器または組織における対応するレセプターを標的とすることができるものである、請求項１０の組換え抗原−Ｐドメインモノマー。
- 挿入された外来シグナルペプチドが、５アミノ酸ＣＮＧＲＣである、請求項１１の組換え抗原−Ｐドメインモノマー。
- 化学反応によって、表面露出リシンおよびシステインを介してＰ粒子のループに挿入されている薬物のコンジュゲートをさらに含む、請求項１の組換え抗原−Ｐドメインモノマー。
- 表面ループの少なくとも１個に挿入されたリガンドまたはシグナルペプチド、ならびに表面ループの少なくとも１個に挿入された薬物のコンジュゲートをさらに含み、それによって疾患を有する特定の組織または臓器に薬物を標的化する薬物送達系を提供する、請求項１の組換え抗原−Ｐドメインモノマー。
- ＮＯＲ Ｐドメインモノマーの表面ループをコードする配列の中に少なくとも１対の制限部位を含む、組換えＰドメインモノマーベクター。
- コードされるＮＯＲ Ｐドメインモノマーの表面ループが第一のループ、第二のループおよび第三のループを含み、かつ、該少なくとも１対の制限部位が、該第一のループ、該第二のループおよび該第三のループの少なくとも１つをコードする配列の中にある、請求項１５の組換えＰドメインモノマーベクター。
- 該配列にコードされる表面ループが、該少なくとも１個の表面ループの長さおよび露出を伸長させるスペーサーを含む、請求項１５の組換えＰドメインモノマーベクター。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18556409P | 2009-06-09 | 2009-06-09 | |
| US61/185,564 | 2009-06-09 | ||
| US22469609P | 2009-07-10 | 2009-07-10 | |
| US61/224,696 | 2009-07-10 | ||
| PCT/US2010/038008 WO2010144602A2 (en) | 2009-06-09 | 2010-06-09 | Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529298A JP2012529298A (ja) | 2012-11-22 |
| JP2012529298A5 true JP2012529298A5 (ja) | 2013-07-25 |
| JP5894528B2 JP5894528B2 (ja) | 2016-03-30 |
Family
ID=43309459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515109A Active JP5894528B2 (ja) | 2009-06-09 | 2010-06-09 | 抗原−ノロウイルスｐドメインモノマーおよびダイマー、抗原−ノロウイルスｐ粒子分子、ならびにそれらの製造および使用法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8486421B2 (ja) |
| EP (1) | EP2440582B1 (ja) |
| JP (1) | JP5894528B2 (ja) |
| CN (2) | CN102612525A (ja) |
| WO (1) | WO2010144602A2 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5894528B2 (ja) | 2009-06-09 | 2016-03-30 | チルドレンズ ホスピタル メディカル センター | 抗原−ノロウイルスｐドメインモノマーおよびダイマー、抗原−ノロウイルスｐ粒子分子、ならびにそれらの製造および使用法 |
| CN102791286B (zh) * | 2010-01-21 | 2017-08-08 | 莱戈赛特医药股份有限公司 | 杯状病毒病毒样颗粒上靶定异源抗原的呈递 |
| FI122520B (fi) * | 2010-10-15 | 2012-03-15 | Vesna Blazevic | Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena |
| US9562077B2 (en) * | 2012-07-11 | 2017-02-07 | Children's Hospital Medical Center | Protein complex system for increased immunogenicity and functionality, and methods making and use |
| CN103304642B (zh) * | 2013-06-06 | 2015-01-07 | 黑龙江八一农垦大学 | 猪轮状病毒δvp8*亚单位重组蛋白及其应用 |
| US9321803B2 (en) | 2013-07-12 | 2016-04-26 | Children's Hospital Medical Center | Compositions and methods for inhibiting norovirus infection |
| CN107034198B (zh) * | 2015-07-15 | 2021-03-09 | 长春百克生物科技股份公司 | 一种嵌合诺如病毒p颗粒及其制备和应用 |
| CN106220738A (zh) * | 2016-07-31 | 2016-12-14 | 中国医学科学院医学生物学研究所 | Ev71中和抗原表位与诺如病毒p结构域嵌合载体的构建和表达方法 |
| WO2018182983A1 (en) | 2017-03-28 | 2018-10-04 | Children's Hospital Medical Center | Norovirus s particle based vaccines and methods of making and using same |
| US20210269488A1 (en) * | 2018-07-13 | 2021-09-02 | The Trustees Of Indiana University | Recombinant rotavirus expression system and recombinant rotaviruses |
| JP7190674B2 (ja) * | 2018-08-23 | 2022-12-16 | パナソニックＩｐマネジメント株式会社 | ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| EP4087604A4 (en) * | 2020-01-08 | 2023-11-01 | Bharat Biotech International Limited | COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550019A (en) | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
| US4769238A (en) * | 1981-08-04 | 1988-09-06 | The Regents Of The University Of California | Synthesis of human virus antigens by yeast |
| US4916213A (en) | 1983-02-22 | 1990-04-10 | Xoma Corporation | Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof |
| US4547367A (en) * | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis B core antigen vaccine |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US5338689A (en) | 1987-08-24 | 1994-08-16 | Stiftung Fur Diagnostische Forschung | Method and card for detecting antigens and/or antibodies |
| ZA896668B (en) | 1988-09-01 | 1990-06-27 | Molecular Therapeutics Inc | A human rhinovirus receptor protein that inhibits virus infectivity |
| US5068191A (en) | 1989-08-31 | 1991-11-26 | The Biomembrane Institute | Purified histo-blood group a glycosyltransferase and antibodies thereto |
| CA2029219A1 (en) * | 1989-11-08 | 1991-05-09 | Mary K. Estes | Methods and reagents to detect and characterize norwalk and related viruses |
| US6572862B1 (en) * | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| JP3310281B2 (ja) * | 1989-11-08 | 2002-08-05 | ベイラー カレッジ オブ メディシン | ノーワーク及び関連のウィルスを検出し同定するための方法と試薬 |
| FR2677767B1 (fr) | 1991-06-11 | 1994-10-14 | Biotechnologie Ste Europeenne | Procede de detection de l'infection par le virus de la diarrhee bovine, sequence nucleotidique codant pour une proteine induite par l'infection par ce virus et proteines et antigenes recombinants s'y rapportant . |
| WO1993000077A1 (en) | 1991-06-21 | 1993-01-07 | University Of Cincinnati | Orally administrable therapeutic proteins and method of making |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
| US5374532A (en) | 1992-08-31 | 1994-12-20 | The Biomembrane Institute | Method for determining susceptibility to escherichia coli urinary tract infections and method for diagnosing secretors and nonsecretors |
| US5367054A (en) | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
| DE4335025A1 (de) | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
| US5750394A (en) | 1994-05-20 | 1998-05-12 | The Mount Sinai Medical Center | Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| EP0845995A1 (en) | 1995-08-18 | 1998-06-10 | Dr. Rentschler Biotechnologie GmbH | Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the ifn-receptor and means for diagnosis of an hiv infection |
| US5891862A (en) | 1996-03-15 | 1999-04-06 | Geltex Pharmaceuticals, Inc. | Polyvalent polymers for the treatment of rotavirus infection |
| IL118625A0 (en) | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibodies |
| US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| US6045854A (en) | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
| US20020019991A1 (en) | 1998-04-30 | 2002-02-14 | Abbott Laboratories | Compositions containing an alpha 1,2-fucose linkage and uses thereof |
| US6593080B1 (en) * | 1999-02-01 | 2003-07-15 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Diagnosis, prevention and treatment of calicivirus infection in humans |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CN1330080A (zh) * | 2000-06-19 | 2002-01-09 | 上海博德基因开发有限公司 | 一种新的多肽——人含p结构域的蛋白10和编码这种多肽的多核苷酸 |
| US6946266B2 (en) | 2000-12-20 | 2005-09-20 | Fred Hutchinson Cancer Research Center | Gene transfer in chicken bursal stem cells |
| EP2263465A1 (en) | 2001-07-06 | 2010-12-22 | Sloan-Kettering Institute for Cancer Research | Polyvalent conjugate vaccine for cancer |
| EP1532279B1 (en) | 2002-05-31 | 2011-02-16 | Children's Hospital Medical Center | Method, composition and kit for antigenic binding of norwalk-like viruses |
| US7977098B2 (en) * | 2002-05-31 | 2011-07-12 | Children's Hospital Medical Center | Antigenic binding patterns of norovirus to human histo-blood group antigens |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US20080050808A1 (en) * | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| WO2005004509A1 (en) | 2003-07-03 | 2005-01-13 | Sung-Chul Sohn | System and method for zone-based personalized information providing |
| CA2541753A1 (en) | 2003-07-10 | 2005-01-20 | Michelle Alfa | Combination therapy for gastroenteric diseases caused by microorganisms |
| US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| WO2005030806A2 (en) * | 2003-09-24 | 2005-04-07 | Montana State University | Norovirus monoclonal antibodies and peptides |
| WO2006138514A2 (en) * | 2005-06-16 | 2006-12-28 | Children's Hospital Medical Center | Novel norovirus particle for use as an antiviral or vaccine |
| US20070231320A1 (en) | 2006-04-03 | 2007-10-04 | Cook Mark E | Eggs having increased antibody titer and methods for making same |
| US20110152263A1 (en) | 2006-11-16 | 2011-06-23 | Xi Jiang | Composition and method for inhibiting norovirus infection |
| US8475789B2 (en) | 2008-01-22 | 2013-07-02 | Multimerics Aps | Products and methods to prevent infections |
| ATE531570T1 (de) | 2009-01-14 | 2011-11-15 | Magna Auteca Ag | Antrieb für ein zu verstellendes bauteil |
| JP5894528B2 (ja) | 2009-06-09 | 2016-03-30 | チルドレンズ ホスピタル メディカル センター | 抗原−ノロウイルスｐドメインモノマーおよびダイマー、抗原−ノロウイルスｐ粒子分子、ならびにそれらの製造および使用法 |
-
2010
- 2010-06-09 JP JP2012515109A patent/JP5894528B2/ja active Active
- 2010-06-09 WO PCT/US2010/038008 patent/WO2010144602A2/en active Application Filing
- 2010-06-09 CN CN2010800353022A patent/CN102612525A/zh active Pending
- 2010-06-09 US US12/797,396 patent/US8486421B2/en active Active
- 2010-06-09 CN CN201710198133.8A patent/CN107043408B/zh active Active
- 2010-06-09 EP EP10786797.0A patent/EP2440582B1/en active Active
-
2013
- 2013-06-24 US US13/924,906 patent/US9096644B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529298A5 (ja) | ||
| Kang et al. | Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates | |
| Steinmetz et al. | PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo | |
| Raman et al. | Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles | |
| EP2308900B1 (en) | Immunogenic compositions and methods of use | |
| JP2023513693A (ja) | ＳＡＲＳ－ＣｏＶ－２ワクチン | |
| JP5890407B2 (ja) | 呼吸器合胞体ウイルス抗原組成物および方法 | |
| JP2020517635A5 (ja) | ||
| Cho et al. | Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers | |
| JP2011521662A5 (ja) | ||
| Azuar et al. | Poly (hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery | |
| JP2008521426A5 (ja) | ||
| Wang et al. | Cell penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination | |
| JP6228967B2 (ja) | 抗原性組成物および方法 | |
| Metz et al. | Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses | |
| Metz et al. | Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype | |
| Cho et al. | Synthesis of well-defined (nitrilotriacetic acid)-end-functionalized polystyrenes and their bioconjugation with histidine-tagged green fluorescent proteins | |
| JP2016504993A5 (ja) | ||
| Lee et al. | Virus-mimetic polymer nanoparticles displaying hemagglutinin as an adjuvant-free influenza vaccine | |
| JP6934862B2 (ja) | 抗マラリア組成物および方法 | |
| Verma et al. | Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB | |
| Narayanan et al. | Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy | |
| Tessarollo et al. | Nonreplicating adenoviral vectors: improving tropism and delivery of cancer gene therapy | |
| Kovalenko et al. | Vaccine candidate against COVID-19 based on structurally modified plant virus as an adjuvant | |
| JP2013529178A5 (ja) |